Manitobans, like all Canadians, have no choice but to consider what will be impacted by Donald Trump's proposed tariffs. In ...

Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug ...

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

Health disparities in marginalized communities are rooted in systemic factors such as discrimination and unequal access to ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

Key Takeaways Merck's stock rose 2% Monday on the back of positive data from a study of a new hypertension drug. MRK stock ...

It's been nearly five years since the pandemic started, but COVID-19 doesn't take a break over the holidays. From shopping to ...

The world’s largest pharmaceutical company by 2023 revenue, Pfizer Inc. (PFE) is down more than 13% year-to-date, while the ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

The power of owning dividend-paying stocks is often underappreciated. Consider, for example, that a study by Hartford Funds ...

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Projects focussing on early cancer detection, protecting children from cyberbullying and developing remote working hubs to ...